Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIGAMA Digital Health Solutions in Patients Receiving Atezolizumab
2023-504342-55-00Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and hepatocellular carcinoma (HCC) (2 cohorts), sponsored by Roche. Primary endpoints: Mean difference in change of Week 12 MDASI Total Symptom Interference Score from baseline and At-home treatment adoption at Cycle 6. Started Feb 2024; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-504342-55-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504342-55-00.